Myovant Sciences Ltd. (MYOV)
Myovant Sciences Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in London, GB. The stock last traded at $26.98, down 0.04% on the session, giving a market capitalisation of $2.62B. On trailing twelve-month figures it carries a trailing P/E of -12.15, a net margin of -89.2%. Its beta of 2.15 implies it has historically moved more than the broad market.
Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.
Myovant Sciences Ltd. is most often compared with the following Healthcare names: